Although Burkitt's lymphomal is one of the most responsive tumours to chemotherapy, patients with advanced disease have proved difficult to cure.2 3 Previous experience in Iraq is that the survival of patients with non-localised disease has been only 6.9%,4 and other centres in developing countries, using non-intensive chemotherapy with or without radiotherapy, have reported similar results..7
The recent introduction of more intensive chemotherapy regimens has led to much improved survival for children with all categories of nonHodgkin's lymphoma, including those B cell tumours of undifferentiated histology that represent the 'sporadic' form of Burkitt's lymphoma.8 9 Although some authors have claimed that radiotherapy is valuable in the management of children with non-Hodgkin's lymphoma,9 10 two randomised studies have shown no benefit when radiotherapy was delivered to sites of previous bulky tumour, " 12 a finding that complements the clinical observation that primary site recurrence is unusual in this disease. Recurrence most commonly occurs, within six months of diagnosis, in bone marrow or the central nervous system, or both, and is then difficult to control without marrow ablative ('megatherapy') approaches. '3 14 Typical and atypical Burkitt's lymphoma constitutes about one half of all childhood non-Hodgkin's lymphoma presenting to our centre (Al-Saleem T. Unpublished data). Because of dissatisfaction with our previous treatment results, we designed a protocol that incorporated (a) careful staging, (b) the use of 'normal dose' but intensively scheduled chemotherapy with rotating drug combinations, (c) early treatment directed at the central nervous system ('central nervous system prophylaxis') with intrathecal methotrexate and moderately high dose systemic methotrexate, (d) short total duration, and (e) no radiotherapy. Debulking surgery formed no part of the protocol but was carried out in a number of patients who were admitted to the surgical units of our hospital before referral to us. The whole protocol was designed to be suitable for use in our centre in which, for example, facilities for intravenous nutrition and serum methotrexate estimation are not available and to take into account the fact that, in Iraq, parental compliance with prolonged courses of treatment is poor.
The aims of the study were to assess the practicability and toxicity of the treatment regimen in a consecutive series of patients, to determine the complete response and survival rates, and to collect information on patterns of relapse. 1013 Patients Prednisolone weeks thereafter: an attempt was made to alkalinise the urine, using intravenous sodium bicarbonate, during courses 1-5 and 8-9. Chemotherapy was given in 11 courses at one to three weekly intervals (Fig. 1) , with special emphasis on the delivery of the first five courses as soon as possible after blood count recovery (neutrophils >1 0x109/l).
Courses 1, 2, 10, and 11 consisted of 'CHOP' (for details, see Fig. 1 group.bmj.com on April 14, 2017 -Published by http://adc.bmj.com/ Downloaded from was not part of the protocol but was used as 'consolidation therapy' in one patient with testicular involvement who showed an incomplete response to chemotherapy.
Before each course the patients were examined to assess tumour response and blood count, and biochemical tests of renal and liver function were performed. Bone marrow examination was carried out every eight weeks and cerebrospinal fluid cell count and cytology after each lumbar puncture. Supportive care included intravenous fluids and antibiotics, alkalinisation of urine, and blood transfusion, as necessary. Parenteral nutrition was not available.
To determine patterns of relapse, patients who completed chemotherapy had clinical examination, bilateral bone marrow aspiration, and cerebrospinal fluid study at two monthly intervals for six months and chest x ray and intravenous urogram at six months. After six months off treatment patients were monitored clinically.
Results
Diagnosis. All 24 patients fulfilled the clinical criteria for diagnosis of Burkitt's lymphoma, and the diagnosis was confirmed either cytologically (two cases) or histologically (22).
Staging and sites of disease. Five patients had stage II tumour, 12 stage III, and seven stage IV (Table   1) . Eighteen paiients had extranodal abdominal disease, 13 at multiple sites. For diagnosis, four of these children underwent biopsy examinations of other disease sites (three of the jaw and one of bone marrow). In the remaining 14, in whom disease was confined to the abdomen, laparotomy was performed. Of these 14 children, five had resection of all gross abdominal disease, but in the remainder only biopsy examination or partial resection was carried out. The incidence of involvement of the abdominal lymph nodes (five patients) was almost certainly an underestimate because laparotomies in patients with unresectable disease were not exhaustive. There were eight children with involvement of the head and neck (the jaw in seven and tonsils in one), six with involved bone marrow, and one with tumour cells in the cerebrospinal fluid. In contrast to our experience in the United Kingdom multiple simultaneous sampling of bone marrow did not, in this series, increase the yield of positive findings.
Toxicity. There was some serious toxicity related to drugs at the start of chemotherapy, with five fatalities. Two patients developed 'tumour lysis syndrome"6 and died within 24 hours of receiving 'CHOP' course 1. Three others developed fever, II  III  III  III   II  IV  III  III  III   II  III  IV  III  III  IV  IV   IV  III  IV  II  III  II  III 
jaundice, and diarrhoea while neutropenic after 'CHOP' course 1 and, although blood cultures yielded negative results, it was assumed that sepsis was the cause of death. In the surviving patients the interval between 'CHOP' courses 1 and 2 was only 21/2-3 weeks and between courses 2 and 3 was only 2 weeks. After the first 'CHOP' course, treatment was well tolerated, with close adherence to the prescribed schedule and with only seven recorded episodes of toxicity, including one of neutropenia and fever, one of severe oral ulceration with raised serum creatinine concentration after treatment with methotrexate, and one of raised serum creatinine concentration alone after treatment with methotrexate. Thus only three admissions to hospital were required after a total of 144 chemotherapy courses. No adjustments to chemotherapy dose were made during the study.
It should be emphasised that some patients were in very poor general condition (Fig. 2) and that many had recently undergone major surgical procedures. There is little doubt that these factors contributed to the early mortality and morbidity related to chemotherapy. Surprisingly, the mean duration of symptoms, before treatment, in those patients who did not achieve complete remission was the same (four weeks) as in those patients who did. A similar observation has been made in Algerian patients.7
Response (Table 2 ) and survival. Two patients died and a third was lost to follow up without receiving any chemotherapy. In the remaining 21 Months from diagnosis off treatment for two to over 29 months (median 17 months). One child with L3 acute lymphoblastic leukaemia is on continuing ('maintenance') treatment with oral methotrexate/6-mercaptopurine and pulses of L-asparaginase, vincristine, prednisolone, and adriamycin.
Discussion
The design of this schedule was based on a United Kingdom Children's Cancer Study Group multidrug protocol that gave unexpectedly good results (69% two year disease free survival) in patients with non-localised (stage II-IV) abdominal nonHodgkin's lymphoma.12 In that study the addition of radiotherapy did not improve the prognosis. In an attempt to avoid the early bone marrow and central nervous system relapse so characteristic of both endemic and non-endemic Burkitt's lymphoma, the first five courses of our protocol were administered as close together as blood counts allowed and included treatment directed at the central nervous system in the form of intrathecal and moderately high dose systemic methotrexate. Given the intensity of treatment, 'maintenance' chemotherapy was deemed unnecessary. It has been suggested that debulking surgery reduces the relapse rate in patients with Burkitt's lymphoma,17 and laparotomy is still advocated in some centres.18 In our series a higher proportion (4/5) of patients who underwent initial debulking of abdominal disease survived than of those whose tumours were considered inoperable (5/11). The group who underwent debulking, however, included two patients with stage II disease, whereas all patients in the group who did not undergo debulking had stage III or IV tumours. Although numbers are small, the long term disease free survival of these five patients who did not undergo debulking suggests that surgery does not add to chemotherapy when the regimen is of sufficient intensity. This point is of particular importance in girls because the internal genitalia (ovaries, Fallopian tubes, and uterus) are often involved by tumour: had chemotherapy been used as initial treatment in patient 9 rather than surgery, castration, with its disastrous effects on the girl's later physical and psychological development, might have been avoided.
Because 11 of our patients have now been off treatment for more than six months (median 24 months from diagnosis) we hope that most of the 12 long term survivors reported here will prove to be cured. It is especially encouraging that these results, a distinct improvement over our previous experience, have been achieved after only six months of chemotherapy and without radiotherapy. The high incidence of earl4 mortality, which parallels experience in Algeria, might have been reduced by the availability of intravenous feeding, the avoidance of unnecessary surgical intervention before chemotherapy, and more careful monitoring during the post-chemotherapy 'tumour lysis syndrome'.
In a randomised study the United States Children's Cancer Study Group showed that a four drug chemotherapy programme ('COMP') was superior to a 10 drug schedule in the treatment of children with non-localised ' 
